The liver is the body's central metabolic organ: it filters and detoxifies xenobiotics and drugs, synthesizes plasma proteins and clotting factors, produces bile, regulates glucose and lipids, stores glycogen and vitamins; it also has a capacity… Read more.
10 factors with evidence, ordered from highest to lowest effectiveness. Information, not medical advice.
⏱ 2 min read
The liver is the body's central metabolic organ: it filters and detoxifies xenobiotics and drugs, synthesizes plasma proteins and coagulation factors, produces bile, regulates glucose and lipids, and stores glycogen and vitamins; it also has an extraordinary regenerative capacity among human organs. The most prevalent liver disease of the 21st century is neither viral nor alcoholic but nonalcoholic fatty liver disease (NAFLD, now renamed MASLD), which affects 25–30% of the adult population worldwide and more than 50% of people with obesity or diabetes.
Metabolic fatty liver disease (MASLD, formerly NAFLD) is the accumulation of liver fat (>5% of hepatocytes) in people without significant alcohol consumption; it is closely linked to insulin resistance and metabolic syndrome. It can progress to steatohepatitis (MASH/NASH) with inflammation and hepatocyte damage, progressive fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma.
The markers: elevated transaminases (ALT, AST) are a sign, but they can be normal even in advanced stages; ultrasound detects significant steatosis; FibroScan (elastography) assesses fibrosis; indices such as FIB-4 and the NAFLD fibrosis score are useful for stratification.
Significant weight loss: the best-supported intervention. A 5% loss improves steatosis, 7–10% improves inflammation, and 10%+ can reverse fibrosis in some cases.
Mediterranean diet: the pattern with the best evidence for hepatic steatosis. It reduces liver fat as measured by imaging.
Regular physical exercise: aerobic + strength; reduces steatosis independently of weight loss.
Reduce added sugars and concentrated fructose (juices, sugary drinks): hepatic fructose is lipogenic.
Reduce or eliminate alcohol: even moderate consumption significantly worsens steatosis.
Reduce ultra-processed foods.
Coffee (2–3 cups/day): with clinical support for reducing liver fibrosis in prospective cohorts.
Vitamin E (800 IU/day for 96 weeks): the PIVENS trial showed significant histological improvement in non-diabetic NASH. Recommended in hepatology guidelines with caveats.
Omega-3 EPA/DHA: modest support for reducing liver fat.
Berberine: improves hepatic metabolic profile.
Silymarin (milk thistle): with classic support in chronic liver disease.
Curcumin, glycyrrhizin, sulforaphane, TUDCA: with support in various contexts.
Coenzyme Q10: in liver disease with mitochondrial dysfunction.
Specific probiotics: growing support for steatosis.
Hepatitis B and C now have effective antiviral treatments; advanced cirrhosis requires specialized hepatology management. Alcoholic liver disease fundamentally requires alcohol cessation (the most effective intervention). Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and others require specialized treatment.
An important warning: several popular supplements can cause significant idiosyncratic hepatotoxicity: green tea extracts at high doses, kava, guazuma herb, herbal weight-loss supplements, anabolic steroids, high doses of vitamin A, high-dose niacin in sustained-release formulation, and many others. The popular notion that "natural = harmless" is incorrect. People with liver disease should review all supplements carefully with their doctor.
Liver health in the 21st century depends mainly on avoiding the metabolic cascade (obesity, insulin resistance, metabolic syndrome): healthy weight, Mediterranean diet, regular exercise, moderate or no alcohol, avoiding ultra-processed foods and added sugars, and not overusing hepatotoxic drugs. Hepatic steatosis is highly reversible in early stages with lifestyle changes; advanced liver disease requires specialized hepatology care.
⏱ 2 min read
The liver is the body's central metabolic organ: it filters and detoxifies xenobiotics and drugs, synthesizes plasma proteins and coagulation factors, produces bile, regulates glucose and lipids, and stores glycogen and vitamins; it also has an extraordinary regenerative capacity among human organs. The most prevalent liver disease of the 21st century is neither viral nor alcoholic but nonalcoholic fatty liver disease (NAFLD, now renamed MASLD), which affects 25–30% of the adult population worldwide and more than 50% of people with obesity or diabetes.
Metabolic fatty liver disease (MASLD, formerly NAFLD) is the accumulation of liver fat (>5% of hepatocytes) in people without significant alcohol consumption; it is closely linked to insulin resistance and metabolic syndrome. It can progress to steatohepatitis (MASH/NASH) with inflammation and hepatocyte damage, progressive fibrosis, cirrhosis, and, in some cases, hepatocellular carcinoma.
The markers: elevated transaminases (ALT, AST) are a sign, but they can be normal even in advanced stages; ultrasound detects significant steatosis; FibroScan (elastography) assesses fibrosis; indices such as FIB-4 and the NAFLD fibrosis score are useful for stratification.
Significant weight loss: the best-supported intervention. A 5% loss improves steatosis, 7–10% improves inflammation, and 10%+ can reverse fibrosis in some cases.
Mediterranean diet: the pattern with the best evidence for hepatic steatosis. It reduces liver fat as measured by imaging.
Regular physical exercise: aerobic + strength; reduces steatosis independently of weight loss.
Reduce added sugars and concentrated fructose (juices, sugary drinks): hepatic fructose is lipogenic.
Reduce or eliminate alcohol: even moderate consumption significantly worsens steatosis.
Reduce ultra-processed foods.
Coffee (2–3 cups/day): with clinical support for reducing liver fibrosis in prospective cohorts.
Vitamin E (800 IU/day for 96 weeks): the PIVENS trial showed significant histological improvement in non-diabetic NASH. Recommended in hepatology guidelines with caveats.
Omega-3 EPA/DHA: modest support for reducing liver fat.
Berberine: improves hepatic metabolic profile.
Silymarin (milk thistle): with classic support in chronic liver disease.
Curcumin, glycyrrhizin, sulforaphane, TUDCA: with support in various contexts.
Coenzyme Q10: in liver disease with mitochondrial dysfunction.
Specific probiotics: growing support for steatosis.
Hepatitis B and C now have effective antiviral treatments; advanced cirrhosis requires specialized hepatology management. Alcoholic liver disease fundamentally requires alcohol cessation (the most effective intervention). Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and others require specialized treatment.
An important warning: several popular supplements can cause significant idiosyncratic hepatotoxicity: green tea extracts at high doses, kava, guazuma herb, herbal weight-loss supplements, anabolic steroids, high doses of vitamin A, high-dose niacin in sustained-release formulation, and many others. The popular notion that "natural = harmless" is incorrect. People with liver disease should review all supplements carefully with their doctor.
Liver health in the 21st century depends mainly on avoiding the metabolic cascade (obesity, insulin resistance, metabolic syndrome): healthy weight, Mediterranean diet, regular exercise, moderate or no alcohol, avoiding ultra-processed foods and added sugars, and not overusing hepatotoxic drugs. Hepatic steatosis is highly reversible in early stages with lifestyle changes; advanced liver disease requires specialized hepatology care.